Literature DB >> 15102494

Novel strategies for the pharmacological management of type 2 diabetes.

Arash Nourparvar1, Angela Bulotta, Umberto Di Mario, Riccardo Perfetti.   

Abstract

Type 2 diabetes is characterized by high concentrations of glucose in the blood, which is caused by decreased secretion of insulin from the pancreas and decreased insulin action. This condition is prevalent worldwide and is associated with morbidity and mortality secondary to complications such as myocardial infarction, stroke and end-stage renal disease. The importance of tight control of blood glucose in either preventing or delaying the progression of complications is recognized. Currently, there are many therapeutic options to treat hyperglycemia in type 2 diabetes. However, tight control is difficult to achieve and is often associated with side-effects. Recent advances in understanding insulin secretion, action and signaling have led to the development of new pharmacological agents. In this article, we review new molecules that are promising candidates for the future management of diabetes, focusing on their mechanism of action, efficacy, safety profile and potential benefits compared with pharmacological agents that are available currently.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15102494     DOI: 10.1016/j.tips.2003.12.007

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  2 in total

Review 1.  New drugs for type 2 diabetes mellitus: what is their place in therapy?

Authors:  Andrew J Krentz; Mayank B Patel; Clifford J Bailey
Journal:  Drugs       Date:  2008       Impact factor: 9.546

2.  Pharmacological and Toxicological Threshold of Bisammonium Tetrakis 4-(N,N-Dimethylamino)pyridinium Decavanadate in a Rat Model of Metabolic Syndrome and Insulin Resistance.

Authors:  Samuel Treviño; Alfonso Díaz; Eduardo Sánchez-Lara; Víctor Enrique Sarmiento-Ortega; José Ángel Flores-Hernández; Eduardo Brambila; Francisco J Meléndez; Enrique González-Vergara
Journal:  Bioinorg Chem Appl       Date:  2018-06-19       Impact factor: 7.778

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.